Skip to main content

Harpoon Therapeutics, Inc.

HARPDelisted Mar 11, 2024
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001708493

Harpoon Therapeutics, Inc. was delisted on Mar 11, 2024; its insiders filed their last Form 4 on Mar 11, 2024; 41 institutions reported holding it in 13F filings for Q4 2023, worth $175.5M in total; no superinvestor held it.

Q4 2023 vs. Q3 2023

How the institutions holding Harpoon Therapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of HARP: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders3241+9
Shares1.87M15.8M+13.9M (+744.9%)
Value$7.53M$175.5M+$167.9M (+2,229.2%)

New holders (16)

Institutions that held Harpoon Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to HARP in Q4 2023
InstitutionSharesValue% of portfolio
Ra Capital Management, L.P.1,500,000$17.1M0.27%
Commodore Capital LP1,500,000$17.1M1.49%
Soleus Capital Management, L.P.820,638$9.33M1.04%
Blackstone Group Inc.815,000$9.27M0.04%
Ally Bridge Group (NY) LLC428,400$4.87M3.51%
Adage Capital Partners GP, L.L.C.300,000$3.41M0.01%
Goldman Sachs Group Inc48,948$556.5K0.00%
Citigroup Inc39,222$446.0K0.00%
Two Sigma Investments, LP27,042$307.5K0.00%
Standard Life Aberdeen plc25,991$295.5K0.00%
Northern Trust Corp24,080$273.8K0.00%
Charles Schwab Investment Management Inc11,401$129.6K0.00%
Caxton Corp13,176$129.3K0.70%
Cubist Systematic Strategies, LLC10,476$119.1K0.00%
BIT Capital GmbH7,407$84.2K0.01%
Barclays PLC105$1.19K0.00%

Sold out (7)

Institutions that held Harpoon Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of HARP in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
OrbiMed Advisors LLC62,121$250.3K
Acadian Asset Management LLC7,670$29.0K
Tower Research Capital LLC (TRC)706$2.85K
Beaird Harris Wealth Management, LLC7$29
Qube Research & Technologies Ltd5$20
Royal Bank of Canada80$0
Hantz Financial Services, Inc.2$0